Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Potravitug - Memo Therapeutics

Next Previous
Drug Profile

Potravitug - Memo Therapeutics

Alternative Names: AntiBKV; AntiBKV - Memo Therapeutics; BK virus-neutralizing antibody - Memo Therapeutics; MTX-005

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memo Therapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus attachment inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Polyomavirus infections

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Polyomavirus-infections(In volunteers) in Australia (IV, Infusion)
  • 18 Oct 2024 Memo Therapeutics plans End of phase II meeting with the US FDA, in September 2025 (Memo Therapeutics communication, October 2024)
  • 18 Oct 2024 Memo Therapeutics plans to initiate phase III trial for Polyomavirus infections, in September 2025 (Memo Therapeutics communication, October 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top